906 related articles for article (PubMed ID: 10890375)
1. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumoural activity of peripheral blood mononuclear cells against melanoma cells: discrepant in-vitro and in-vivo effects.
Joseph-Pietras D; Carlier A; Madoulet C; Albert P
Melanoma Res; 2006 Aug; 16(4):325-33. PubMed ID: 16845328
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma.
Charak BS; Sadowski RM; Mazumder A
Cancer Res; 1992 Dec; 52(23):6482-6. PubMed ID: 1384963
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
7. IL-2 inhibits the induction of systemic antitumour immunity by IL-4 in the peritumoural treatment of experimental melanoma.
Zaloom Y; Gallagher G
Anticancer Res; 1993; 13(4):1081-5. PubMed ID: 8352529
[TBL] [Abstract][Full Text] [Related]
8. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma.
Perrotta C; Bizzozero L; Falcone S; Rovere-Querini P; Prinetti A; Schuchman EH; Sonnino S; Manfredi AA; Clementi E
Cancer Res; 2007 Aug; 67(16):7559-64. PubMed ID: 17699758
[TBL] [Abstract][Full Text] [Related]
10. TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect.
Penafuerte C; Galipeau J
Cancer Immunol Immunother; 2008 Aug; 57(8):1197-206. PubMed ID: 18214474
[TBL] [Abstract][Full Text] [Related]
11. Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice.
Mitrus I; Delić K; Wróbel N; Missol-Kolka E; Szala S
Acta Biochim Pol; 2006; 53(2):357-60. PubMed ID: 16733559
[TBL] [Abstract][Full Text] [Related]
12. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
13. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effect of 4-1BBL combined with Hsp70-tumor antigen peptides on pulmonary metastasis of melanoma in mice].
Qiu H; Zhang GM; Zhang H; Yuan Y; Li D; Feng ZH
Ai Zheng; 2005 Jul; 24(7):781-6. PubMed ID: 16004800
[TBL] [Abstract][Full Text] [Related]
15. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
[TBL] [Abstract][Full Text] [Related]
18. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
